American heart journal最新文献

筛选
英文 中文
TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery: the TRACS trial: TAVI in centers without on-site cardiac surgery. 有无现场心脏手术的导管主动脉瓣植入术:TRACS 试验:无现场心脏手术中心的 TAVI。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-11-04 DOI: 10.1016/j.ahj.2024.10.019
Gianmarco Iannopollo, Marta Cocco, Alessandro Leone, Salvatore Saccà, Domenico Mangino, Andrea Picchi, Matteo Rocco Reccia, Massimo Fineschi, Emanuele Meliga, Andrea Audo, Giampiero Nobile, Carlo Tumscitz, Carlo Penzo, Francesco Saia, Andrea Rubboli, Carolina Moretti, Luigi Vignali, Giampaolo Niccoli, Paolo Cimaglia, Andrea Rognoni, Daniela Aschieri, Daniele Iaccarino, Filippo Ottani, Caterina Cavazza, Ferdinando Varbella, Gioel Gabrio Secco, Leonardo Bolognese, Ugo Limbruno, Vincenzo Guiducci, Gianluca Campo, Gianni Casella
{"title":"TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery: the TRACS trial: TAVI in centers without on-site cardiac surgery.","authors":"Gianmarco Iannopollo, Marta Cocco, Alessandro Leone, Salvatore Saccà, Domenico Mangino, Andrea Picchi, Matteo Rocco Reccia, Massimo Fineschi, Emanuele Meliga, Andrea Audo, Giampiero Nobile, Carlo Tumscitz, Carlo Penzo, Francesco Saia, Andrea Rubboli, Carolina Moretti, Luigi Vignali, Giampaolo Niccoli, Paolo Cimaglia, Andrea Rognoni, Daniela Aschieri, Daniele Iaccarino, Filippo Ottani, Caterina Cavazza, Ferdinando Varbella, Gioel Gabrio Secco, Leonardo Bolognese, Ugo Limbruno, Vincenzo Guiducci, Gianluca Campo, Gianni Casella","doi":"10.1016/j.ahj.2024.10.019","DOIUrl":"https://doi.org/10.1016/j.ahj.2024.10.019","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter aortic valve implantation (TAVI) has emerged as an effective and safe treatment for patients with symptomatic aortic stenosis. The indication to TAVI should be agreed upon by a Heart Team, and the procedure should be performed in centers with on-site cardiac surgery. However, TAVI complications requiring emergent cardiac surgery (ECS) have become very rare. Concurrently, access disparities and prolonged waiting times are pressing issues due to increasing clinical demand of TAVI. Many solutions have been proposed and one of them is the possibility of performing TAVI in centers without on-site cardiac surgery.</p><p><strong>Methods and design: </strong>The TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery (TRACS) trial is a prospective, randomized, multicenter, open-label study with blinded adjudicated evaluation of outcomes. Patients with symptomatic severe aortic stenosis and deemed inoperable, at high surgical risk, or presenting with at least one clinical factor compromising the benefit/risk ratio for ECS, will be randomized to undergo TAVI either in centers with or without on-site cardiac surgery. The primary endpoint will be the composite occurrence of all-cause death, stroke, and hospital readmission for cardiovascular causes at one year. The safety endpoint will include death attributable to periprocedural complications actionable by ECS. The study aims to enroll 566 patients.</p><p><strong>Implications: </strong>The TRACS trial aims to address critical gaps in knowledge regarding the safety and efficacy of TAVI procedures performed in centers without on-site cardiac surgery, potentially improving access and outcomes for high-risk patients.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT05751577.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rationale and Design of the DEFIANCE Study: A Randomized Controlled Trial of Mechanical Thrombectomy Versus Anticoagulation Alone for Iliofemoral Deep Vein Thrombosis. DEFIANCE 研究的原理和设计:机械血栓切除术与单纯抗凝治疗髂股深静脉血栓的随机对照试验。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-11-02 DOI: 10.1016/j.ahj.2024.10.016
Steven D Abramowitz, Xhorlina Marko, Donna D'Souza, Sonya Noor, Keith Pereira, Mitchell J Silver, Stuart P Rosenberg, Craig D Markovitz, Thomas Tu, Ido Weinberg, Stephen Black
{"title":"Rationale and Design of the DEFIANCE Study: A Randomized Controlled Trial of Mechanical Thrombectomy Versus Anticoagulation Alone for Iliofemoral Deep Vein Thrombosis.","authors":"Steven D Abramowitz, Xhorlina Marko, Donna D'Souza, Sonya Noor, Keith Pereira, Mitchell J Silver, Stuart P Rosenberg, Craig D Markovitz, Thomas Tu, Ido Weinberg, Stephen Black","doi":"10.1016/j.ahj.2024.10.016","DOIUrl":"https://doi.org/10.1016/j.ahj.2024.10.016","url":null,"abstract":"<p><strong>Background: </strong>Deep vein thrombosis (DVT) is a common medical condition that is associated with clinically significant sequelae, including postthrombotic syndrome (PTS). Anticoagulation alone remains the guideline-recommended treatment for many patients with iliofemoral DVT. Recent technological advances have led to an increase in the use of mechanical thrombectomy for DVT, but mechanical thrombectomy-based procedures have not yet been compared with standard-of-care anticoagulation therapy in randomized studies.</p><p><strong>Methods: </strong>The DEFIANCE study (ClinicalTrials.gov: NCT05701917) is an international and actively enrolling randomized controlled trial (RCT) in lower extremity DVT assessing an interventional strategy that includes mechanical thrombectomy with the ClotTriever System (Inari Medical, Irvine, CA) versus anticoagulation alone. Approximately 300 patients with unilateral iliofemoral DVT and symptom duration ≤12 weeks will be randomized 1:1. Study conduct includes an independent core laboratory for duplex ultrasound assessment, an independent medical monitor for safety adjudication, and evaluation of PTS severity on the Villalta scale using best clinical practices. The primary endpoint is a composite outcome structured as a hierarchal win ratio of 1) the occurrence of treatment failure or therapy escalation as adjudicated by the medical monitor, with failure defined as amputation or gangrene of the target leg or venous thromboembolism-related mortality, and 2) the assessment of PTS severity at the 6-month follow-up visit. In addition to being a component of the primary endpoint, the severity of PTS at 6 months is also evaluated as a stand-alone secondary endpoint. An additional secondary endpoint is a composite of outcomes at the 10-day visit and is structured as a hierarchal win ratio of 1) vessel compressibility on duplex ultrasound, 2) patient-reported pain, and 3) improvement of edema. The safety endpoints are access site complications requiring endovascular or surgical repair and the occurrence through the 30-day visit of mortality, major bleeding, or new symptomatic pulmonary embolism.</p><p><strong>Conclusions: </strong>DEFIANCE will be the first RCT to evaluate a mechanical thrombectomy-based interventional approach versus anticoagulation therapy alone for DVT. The results will inform the treatment of patients with iliofemoral DVT and the prevention of PTS-associated morbidity.</p><p><strong>Trial registration: </strong>DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis (DEFIANCE), ClinicalTrials.gov: NCT05701917, URL: https://clinicaltrials.gov/study/NCT05701917?cond=Deep%20Vein%20Thrombosis&term=defiance&rank=1.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of E-Cigarette, Traditional Cigarettes, and C-Reactive Protein: The Cross Cohort Collaboration. 使用电子烟、传统香烟与 C 反应蛋白:交叉队列协作。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-10-24 DOI: 10.1016/j.ahj.2024.10.012
Zhiqi Yao, Erfan Tasdighi, Zeina A Dardari, John Erhabor, Kunal K Jha, Ngozi Osuji, Tanuja Rajan, Ellen Boakye, Carlos J Rodriguez, Joao A C Lima, Suzanne Judd, Theodore Feldman, Jonathan A Fialkow, Vasan S Ramachandran, Omar El Shahawy, Emelia J Benjamin, Aruni Bhatnagar, Andrew P DeFilippis, Khurram Nasir, Michael J Blaha
{"title":"Use of E-Cigarette, Traditional Cigarettes, and C-Reactive Protein: The Cross Cohort Collaboration.","authors":"Zhiqi Yao, Erfan Tasdighi, Zeina A Dardari, John Erhabor, Kunal K Jha, Ngozi Osuji, Tanuja Rajan, Ellen Boakye, Carlos J Rodriguez, Joao A C Lima, Suzanne Judd, Theodore Feldman, Jonathan A Fialkow, Vasan S Ramachandran, Omar El Shahawy, Emelia J Benjamin, Aruni Bhatnagar, Andrew P DeFilippis, Khurram Nasir, Michael J Blaha","doi":"10.1016/j.ahj.2024.10.012","DOIUrl":"https://doi.org/10.1016/j.ahj.2024.10.012","url":null,"abstract":"<p><p>This cross-sectional study included 18,797 participants from six longitudinal cohorts (CARDIA, FHS Gen III, HCHS/SOL, MESA, MiHeart, and REGARDS). 5,806 of them were with high-sensitivity C-reactive protein (hs-CRP) measurements. We found that among exclusive electronic cigarette (EC) use was associated with significantly lower high-sensitivity C-reactive protein (hs-CRP) levels compared to exclusive combustible cigarette use, suggesting a potentially lower inflammatory burden. hs-CRP levels in dual users and former smokers currently using EC were comparable to those observed in exclusive cigarette smokers. In contrast, individuals who exclusively used ECs showed no significant difference in hs-CRP levels compared to never smokers. These findings have important implications for tobacco regulation, public health, and clinical practice, highlighting the need for continued monitoring of EC-related health impacts.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia. 多中心随机 EVAOLD 试验的原理和设计:评估老年缺血患者的成像指导策略与常规侵入策略。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-10-22 DOI: 10.1016/j.ahj.2024.10.013
Gilles Barone-Rochette, Gerald Vanzetto, Nicolas Danchin, Philippe Gabriel Steg, Olivier Hanon, Clemence Charlon, Sandra David-Tchouda, Gaetan Gavazzi, Tabassome Simon, Jean-Luc Bosson
{"title":"Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia.","authors":"Gilles Barone-Rochette, Gerald Vanzetto, Nicolas Danchin, Philippe Gabriel Steg, Olivier Hanon, Clemence Charlon, Sandra David-Tchouda, Gaetan Gavazzi, Tabassome Simon, Jean-Luc Bosson","doi":"10.1016/j.ahj.2024.10.013","DOIUrl":"https://doi.org/10.1016/j.ahj.2024.10.013","url":null,"abstract":"<p><strong>Background: </strong>The management of myocardial infarction without ST segment elevation (NSTEMI) in elderly patients remains challenging, in particular the benefit/risk balance of routine revascularization remains uncertain.</p><p><strong>Study design: </strong>EVAOLD is s a multicenter, prospective, open-label trial with 2 parallel arms in NSTEMI patients ≥ 80 years of age. The aim of the trial is to test whether a strategy of selective invasive management guided by ischemia stress imaging (IMG group) will be non-inferior in preventing Major Adverse Cardiac and Cerebrovascular Events (MACCE, ie all-cause death, non-fatal myocardial infarction, non-fatal stroke) rates at 1 year compared with a routine invasive strategy (INV Group). Geriatric assessment and cost- effectiveness analysis will also be performed. A sample size of 1756 patients (assuming a 10% rate of patients lost to follow-up) is needed to show non-inferiority with 80% power. Non-inferiority based on exponential survival curves will be declared if the upper limit of the one-sided 97.5% confidence interval for the hazard ratio is lower than 1.24, corresponding to a non-inferiority margin of 7% in absolute difference and an event rate of 40% in the INV group.</p><p><strong>Conclusion: </strong>EVAOLD is a nationwide, prospective, open-label trial testing the non-inferiority of a strategy of selective invasive management guided by ischemia stress imaging versus routine invasive strategy in elderly NSTEMI patients.</p><p><strong>Clinicaltrials: </strong>gov Identifier: NCT03289728.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brief report: U.S. trends in use of colchicine by cardiologists and other specialties, 2018 to 2024 简要报告:2018年至2024年美国心脏病专家和其他专科医生使用秋水仙碱的趋势。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-10-22 DOI: 10.1016/j.ahj.2024.10.011
Michael Khorsandi MD , Omar Mhaimeed MD , Omar Dzaye MD, MPH, PhD , Erfan Tasdighi MD , G. Caleb Alexander MD, MS , Michael J. Blaha MD, MPH
{"title":"Brief report: U.S. trends in use of colchicine by cardiologists and other specialties, 2018 to 2024","authors":"Michael Khorsandi MD ,&nbsp;Omar Mhaimeed MD ,&nbsp;Omar Dzaye MD, MPH, PhD ,&nbsp;Erfan Tasdighi MD ,&nbsp;G. Caleb Alexander MD, MS ,&nbsp;Michael J. Blaha MD, MPH","doi":"10.1016/j.ahj.2024.10.011","DOIUrl":"10.1016/j.ahj.2024.10.011","url":null,"abstract":"<div><div>Colchicine has emerged as an effective agent for reducing ASCVD based on recent large cardiovascular outcome trials and exerts its benefit through targeting inflammation. In light of the robust body of data and FDA approval of low-dose colchicine for ASCVD prevention, this paper aimed to use the National Prescription Audit to quantify the volume and trends of colchicine prescriptions dispensed through U.S. retail pharmacies between March 2018 and February 2024. Despite a 6% increase in total monthly prescriptions since 2020, which was driven primarily by cardiologists, this specialty still represents only 2.8%-4% of the national monthly precription totals with small absolute numbers (ie estimated ∼4000 incremental prescriptions/month since 2020), suggesting limited cardiologist adoption of colchicine for ASCVD prevention despite favorable clinical trial data.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"279 ","pages":"Pages 76-80"},"PeriodicalIF":3.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A randomized embedded multifactorial adaptive platform for extra corporeal membrane oxygenation (REMAP ECMO) - design and rationale of the left ventricular unloading trial domain. 体外膜氧合的随机嵌入式多因素自适应平台(REMAP ECMO)--左心室减压试验领域的设计与原理。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-10-22 DOI: 10.1016/j.ahj.2024.10.010
Myrthe P J van Steenwijk, Joost van Rosmalen, Carlos V Elzo Kraemer, Dirk W Donker, Jeannine A J M Hermens, Adriaan O Kraaijeveld, Jacinta J Maas, Sakir Akin, Leon J Montenij, Alexander P J Vlaar, Walter M van den Bergh, Annemieke Oude Lansink-Hartgring, Jesse de Metz, Niek Voesten, Eric Boersma, Erik Scholten, Albertus Beishuizen, Chris P H Lexis, Harlinde Peperstraete, Simon Schiettekatte, Roberto Lorusso, Diederik A M P J Gommers, Dick Tibboel, Rudolf A de Boer, Nicolas M D A Van Mieghem, Christiaan L Meuwese
{"title":"A randomized embedded multifactorial adaptive platform for extra corporeal membrane oxygenation (REMAP ECMO) - design and rationale of the left ventricular unloading trial domain.","authors":"Myrthe P J van Steenwijk, Joost van Rosmalen, Carlos V Elzo Kraemer, Dirk W Donker, Jeannine A J M Hermens, Adriaan O Kraaijeveld, Jacinta J Maas, Sakir Akin, Leon J Montenij, Alexander P J Vlaar, Walter M van den Bergh, Annemieke Oude Lansink-Hartgring, Jesse de Metz, Niek Voesten, Eric Boersma, Erik Scholten, Albertus Beishuizen, Chris P H Lexis, Harlinde Peperstraete, Simon Schiettekatte, Roberto Lorusso, Diederik A M P J Gommers, Dick Tibboel, Rudolf A de Boer, Nicolas M D A Van Mieghem, Christiaan L Meuwese","doi":"10.1016/j.ahj.2024.10.010","DOIUrl":"10.1016/j.ahj.2024.10.010","url":null,"abstract":"<p><strong>Background: </strong>The use of Extracorporeal Membrane Oxygenation (ECMO) remains associated with high rates of complications, weaning failure and mortality which can be partly explained by a knowledge gap on how to properly manage patients on ECMO support. To address relevant patient management issues, we designed a \"Randomized Embedded Multifactorial Adaptive Platform (REMAP)\" in the setting of ECMO (REMAP ECMO) and a first embedded randomized controlled trial (RCT) investigating the effects of routine early left ventricular (LV) unloading through intra-aortic balloon pumping (IABP).</p><p><strong>Methods: </strong>REMAP ECMO describes a registry-based platform allowing for the embedding of multiple response adaptive RCTs (trial domains) which can perpetually address the effect of relevant patient management issues on ECMO weaning success. A first trial domain studies the effects of LV unloading by means of an IABP as an adjunct to veno-arterial (V-A) ECMO versus V-A ECMO alone on ECMO weaning success at 30 days in adult cardiogenic shock patients admitted to the Intensive Care Unit (ICU). The primary outcome of this trial is \"successful weaning from ECMO\" being defined as a composite of survival without the need for mechanical circulatory support, heart transplantation, or left ventricular assist device (LVAD) at 30 days after initiation of ECMO. Secondary outcomes include the need for interventional escalation of LV unloading strategy, mechanistic endpoints, survival characteristics until 1 year after ECMO initiation, and quality of life. Trial data will be analysed using a Bayesian statistical framework. The adaptive design allows for a high degree of flexibility, such as response adaptive randomization and early stopping of the trial for efficacy or futility. The REMAP ECMO LV unloading study is approved by the Medical Ethical Committee of the Erasmus Medical Center and is publicly registered.</p><p><strong>Conclusion: </strong>This REMAP ECMO trial platform enables the efficient roll-out of multiple RCTs on relevant patient management issues. A first embedded trial domain will compare routine LV unloading by means of an IABP as an adjunct to V-A ECMO versus V-A ECMO alone.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT05913622.</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":"81-93"},"PeriodicalIF":3.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fontan circulation and systemic disease – a retrospective cohort analysis over 35 years of follow-up 丰唐循环与全身性疾病--35年随访的回顾性队列分析:35年后的丰唐全身性疾病。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-10-17 DOI: 10.1016/j.ahj.2024.10.008
Gruschen R. Veldtman MBChB, FRCP , Ali Abualsaud MD , Sarah Cohen MD, PhD , Maria Victoria Ordonez MD , Liming Guo MSc , Chao Li MSc , Aihua Liu PhD , Jasmine Grewal MD , Michelle Gurvitz MD , Judith Therrien MD , Ariane Marelli MD, MPH
{"title":"Fontan circulation and systemic disease – a retrospective cohort analysis over 35 years of follow-up","authors":"Gruschen R. Veldtman MBChB, FRCP ,&nbsp;Ali Abualsaud MD ,&nbsp;Sarah Cohen MD, PhD ,&nbsp;Maria Victoria Ordonez MD ,&nbsp;Liming Guo MSc ,&nbsp;Chao Li MSc ,&nbsp;Aihua Liu PhD ,&nbsp;Jasmine Grewal MD ,&nbsp;Michelle Gurvitz MD ,&nbsp;Judith Therrien MD ,&nbsp;Ariane Marelli MD, MPH","doi":"10.1016/j.ahj.2024.10.008","DOIUrl":"10.1016/j.ahj.2024.10.008","url":null,"abstract":"<div><h3>Background</h3><div>The Fontan operation provides lifesaving palliation for individuals with single ventricle (SV) physiology. Given recent concerns of systemic disease (SD) for patients with a Fontan circulation, we sought to (1) quantify the increase in SD incidence associated with the Fontan circulation; (2) identify the risk factor of SD; (3) assess the association between SD and mortality in patients with a Fontan circulation.</div></div><div><h3>Methods</h3><div>A matched retrospective cohort study design was adopted. From the Quebec Congenital Heart Disease (CHD) Database with up to 35 years of follow-up, patients who survived at least 30 days after the Fontan operation were identified. For each Fontan patient, patients with isolated ventricular septal defect (VSD) with the same sex and age were identified and 20 of them were randomly selected to form the control group. The presence of SD was defined as at least 1 hospitalization due to extra-cardiac complications including liver, respiratory, gastrointestinal or renal disease. Time-to-event analysis including Kaplan-Meier curve analysis and Cox proportional hazard models were conducted to assess the cumulative risk of SD, risk factors of SD, and the association between SD and 10-year mortality.</div></div><div><h3>Results</h3><div>A total of 533 patients with Fontan circulation were identified and matched with 10,280 VSD patients. The cumulative probabilities of SD at 10- and 35-years follow-up were 59.02% and 89.66% in patients with a Fontan circulation, 4 to 7 times of the probabilities in VSD patients (8.68% and 23.34%, respectively; LogRank tests <em>P</em> &lt; .0001). In Fontan patients, cardiovascular complications were associated with a 4.1-fold (95% CI: 3.52-4.88) higher risk of developing SD. Multisystem disease (&gt;1 extra-cardiac organ affected) disease was associated with a 3.38-fold (95%CI: 1.73-6.60) increase in 10-year mortality risk when comparing to the absence of SD.</div></div><div><h3>Conclusions</h3><div>This population-based study demonstrated that patients with a Fontan circulation had increased risk of SD, which in turn led to higher risk of mortality. These findings underscore the need for more systematic surveillance of cardiac and systemic disease for patients after Fontan operation.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"279 ","pages":"Pages 40-49"},"PeriodicalIF":3.7,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiologist perceptions on automated alerts and messages to improve heart failure care 心脏病专家对自动提示和信息改善心衰护理的看法。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-10-16 DOI: 10.1016/j.ahj.2024.10.007
Samuel D. Maidman MD , Saul Blecker MD , Harmony R. Reynolds MD , Lawrence M. Phillips MD , Margaret M. Paul PhD , Arielle R. Nagler MD , Adam Szerencsy DO , Archana Saxena MD , Leora I. Horwitz MD , Stuart D. Katz MD , Amrita Mukhopadhyay MD
{"title":"Cardiologist perceptions on automated alerts and messages to improve heart failure care","authors":"Samuel D. Maidman MD ,&nbsp;Saul Blecker MD ,&nbsp;Harmony R. Reynolds MD ,&nbsp;Lawrence M. Phillips MD ,&nbsp;Margaret M. Paul PhD ,&nbsp;Arielle R. Nagler MD ,&nbsp;Adam Szerencsy DO ,&nbsp;Archana Saxena MD ,&nbsp;Leora I. Horwitz MD ,&nbsp;Stuart D. Katz MD ,&nbsp;Amrita Mukhopadhyay MD","doi":"10.1016/j.ahj.2024.10.007","DOIUrl":"10.1016/j.ahj.2024.10.007","url":null,"abstract":"<div><h3>Introduction</h3><div>Electronic health record (EHR)-embedded tools are known to improve prescribing of guideline-directed medical therapy (GDMT) for patients with heart failure. However, physicians may perceive EHR tools to be unhelpful and be hesitant to implement these in their practice.</div></div><div><h3>Methods</h3><div>The BETTER CARE-HF trial (NCT05275920) ran from April 28, 2022 to October 26, 2022 at NYU Langone Health outpatient clinics being seen by 180 cardiologists. The trial compared the effectiveness of an Alert during visits, Messages between visits, or usual care with the primary outcome of MRA prescribing. In this study, we sent surveys via electronic mail to cardiologists who either received an Alert or a Message during BETTER CARE-HF (60 cardiologists per survey).</div></div><div><h3>Results</h3><div>Of the 120 cardiologists who were sent the survey, response rate was 27% in the Alert group and 33% in the Message group. A majority of respondents in both the alert and message groups agreed that EHR tools were easy to use (Alert 79%; Message 69%), served as a reminder to prescribe therapy (Alert 77%; Message 77%;), and that the underlying evidence (Alert 86%; Message 62%) and clinical information (Alert 86%; Message 69%) were trustworthy. Overall, 54% agreed with continued use of the Alert, while 31% agreed with continued use of the Message.</div></div><div><h3>Conclusion</h3><div>Cardiologists perceived the EHR tools to be easy to use, helpful, and improve the overall management of their patients with heart failure.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"279 ","pages":"Pages 59-65"},"PeriodicalIF":3.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and rationale of a pragmatic randomized clinical trial of early dronedarone versus usual care to change and improve outcomes in persons with first-detected atrial fibrillation – the CHANGE AFIB study 为改变和改善首次发现心房颤动患者的预后而进行的早期决奈达隆与常规护理的务实性随机临床试验的设计和原理 - CHANGE AFIB 研究。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-10-16 DOI: 10.1016/j.ahj.2024.10.001
Sean D. Pokorney MD, MBA , Hayley Nemeth MS , Karen Chiswell PhD , Christine Albert MD , Nadine Allyn RD, MPH , Rosalia Blanco MBA , Javed Butler MD, MPH, MBA , Hugh Calkins MD , Mitchell S.V. Elkind MD, MS , Gregg C. Fonarow MD , John M. Fontaine MD, MBA , David S. Frankel MD , Gregory J. Fermann MD , Rex Gale SHRM-SCP , Matthew Kalscheur MD , Paulus Kirchhof MD , Andrew Koren MD , Joseph B. Miller MD, MS , Jason Rashkin MD , Andrea M. Russo MD , Jonathan P. Piccini MD, MHS
{"title":"Design and rationale of a pragmatic randomized clinical trial of early dronedarone versus usual care to change and improve outcomes in persons with first-detected atrial fibrillation – the CHANGE AFIB study","authors":"Sean D. Pokorney MD, MBA ,&nbsp;Hayley Nemeth MS ,&nbsp;Karen Chiswell PhD ,&nbsp;Christine Albert MD ,&nbsp;Nadine Allyn RD, MPH ,&nbsp;Rosalia Blanco MBA ,&nbsp;Javed Butler MD, MPH, MBA ,&nbsp;Hugh Calkins MD ,&nbsp;Mitchell S.V. Elkind MD, MS ,&nbsp;Gregg C. Fonarow MD ,&nbsp;John M. Fontaine MD, MBA ,&nbsp;David S. Frankel MD ,&nbsp;Gregory J. Fermann MD ,&nbsp;Rex Gale SHRM-SCP ,&nbsp;Matthew Kalscheur MD ,&nbsp;Paulus Kirchhof MD ,&nbsp;Andrew Koren MD ,&nbsp;Joseph B. Miller MD, MS ,&nbsp;Jason Rashkin MD ,&nbsp;Andrea M. Russo MD ,&nbsp;Jonathan P. Piccini MD, MHS","doi":"10.1016/j.ahj.2024.10.001","DOIUrl":"10.1016/j.ahj.2024.10.001","url":null,"abstract":"<div><h3>Background</h3><div>While there are several completed clinical trials that address treatment strategies in patients with symptomatic and recurrent atrial fibrillation (AF), there are no randomized clinical trials that address first-line rhythm control of new-onset AF. Recent data suggest that early initiation of rhythm control within 1 year can improve outcomes.</div></div><div><h3>Methods</h3><div>In this open-label pragmatic clinical trial nested within the Get with The Guidelines Atrial Fibrillation registry, approximately 3,000 patients with first-detected AF will be enrolled at approximately 200 sites. Participants will be randomized (1:1) to treatment with dronedarone in addition to usual care versus usual care alone. The primary endpoint will be time to first cardiovascular (CV) hospitalization or death from any cause through 12 months from randomization. Secondary endpoints will include a WIN ratio (all-cause death, ischemic stroke or systemic embolism, heart failure hospitalization, acute coronary hospitalization), CV hospitalization, and all-cause mortality. Patient reported outcomes will be analyzed based on change in Atrial Fibrillation Effect on Quality of Life (AFEQT) and change in Mayo AF-Specific Symptom Inventory (MAFSI) from baseline to 12 months.</div></div><div><h3>Conclusion</h3><div>CHANGE AFIB will determine if treatment with dronedarone in addition to usual care is superior to usual care alone for the prevention of CV hospitalization or death from any cause in patients with first-detected AF. The trial will also determine whether initiation of rhythm control at the time of first-detected AF affects CV events or improves patient reported outcomes.</div></div><div><h3>Trial Registration</h3><div><strong>-</strong> NCT05130268</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"279 ","pages":"Pages 66-75"},"PeriodicalIF":3.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease 动脉粥样硬化性心血管疾病患者低密度脂蛋白胆固醇管理的真实世界探索。
IF 3.7 2区 医学
American heart journal Pub Date : 2024-10-16 DOI: 10.1016/j.ahj.2024.10.009
Nishant P. Shah MD , Hillary Mulder MS , Elizabeth Lydon MS , Karen Chiswell PhD , Xingdi Hu PhD , Zachary Lampron MPH, PMP , Lauren Cohen MA, PMP , Manesh R. Patel MD , Susan Taubes MPH, PMP , Wenliang Song MD , Suresh R. Mulukutla MD , Anum Saeed MD , Daniel P. Morin MD, MPH , Steven M. Bradley MD , Adrian F. Hernandez MD, MHS , Neha J. Pagidipati MD, MPH
{"title":"Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease","authors":"Nishant P. Shah MD ,&nbsp;Hillary Mulder MS ,&nbsp;Elizabeth Lydon MS ,&nbsp;Karen Chiswell PhD ,&nbsp;Xingdi Hu PhD ,&nbsp;Zachary Lampron MPH, PMP ,&nbsp;Lauren Cohen MA, PMP ,&nbsp;Manesh R. Patel MD ,&nbsp;Susan Taubes MPH, PMP ,&nbsp;Wenliang Song MD ,&nbsp;Suresh R. Mulukutla MD ,&nbsp;Anum Saeed MD ,&nbsp;Daniel P. Morin MD, MPH ,&nbsp;Steven M. Bradley MD ,&nbsp;Adrian F. Hernandez MD, MHS ,&nbsp;Neha J. Pagidipati MD, MPH","doi":"10.1016/j.ahj.2024.10.009","DOIUrl":"10.1016/j.ahj.2024.10.009","url":null,"abstract":"<div><h3>Background</h3><div>Although guidelines recommend low-density lipoprotein cholesterol (LDL-C) to be &lt; 70 mg/dL in patients with atherosclerotic cardiovascular disease (ASCVD), the rate of achieving this goal remains suboptimal. We sought to understand real world contemporary practice patterns of LDL-C management in patients with ASCVD, and whether LDL-C testing influenced management across US health systems.</div></div><div><h3>Methods</h3><div>A retrospective cohort study utilizing electronic medical record data from five health systems participating in the CardioHealth Alliance was performed on patients with an LDL-C measurement in 2021 and prior ASCVD. Multivariable regression modeling was used to determine the relationship of clinical factors with achievement of guideline directed LDL-C target. Changes in lipid lowering therapy (LLT) after LDL-C testing were also described.</div></div><div><h3>Results</h3><div>Among 216,074 patients with ASCVD, 129,886 (60.1%) had uncontrolled LDL-C (i.e. ≥ 70 mg/dL). Compared with participants with controlled LDL-C (&lt; 70 mg/dL), those with uncontrolled LDL-C were more frequently female (50.9% vs. 35.1%), or Black (13.7% vs. 10.3%), and less commonly had coronary artery disease as the form of vascular disease (73.0% vs. 83.5% %), heart failure (21.3% vs. 29.1% %), diabetes (34.1% vs. 48.2%), atrial fibrillation (19.3% vs. 26.1%), or chronic kidney disease (25.1% vs. 32.2%). In multivariable analyses, the factors most strongly associated with failure to achieve LDL-C control were female sex (RR 1.13 [95% CI 1.12-1.14] <em>P</em> &lt; .001) and Black race (1.15 [1.14-1.17] <em>P</em> &lt; .001). Among the 53,957 (41.5%) of those with uncontrolled LDL-C ≥70 mg/dL not on lipid lowering therapy (LLT) at baseline, only 21% were initiated on any LLT within 6 months of the uncontrolled LDL-C value.</div></div><div><h3>Conclusions</h3><div>Within 5 diverse large health systems in the CardioHealth Alliance, more than half of the patients with ASCVD had uncontrolled LDL-C with significant disparities based on sex and race at baseline. The vast majority were not initiated on any lipid lowering therapy within 6 months of an elevated test result indicating persistent gaps in care that will likely worsen health inequities in outcomes. This highlights the urgent need for implementation efforts to improve equitable care.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"279 ","pages":"Pages 50-58"},"PeriodicalIF":3.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信